Neurogene (NASDAQ:NGNE) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright assumed coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research note released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $45.00 price target on the stock. HC Wainwright also issued estimates for Neurogene’s Q4 2023 earnings at ($1.66) EPS, FY2023 earnings at ($7.82) EPS, Q1 […]
More Stories
What Battleground Voters Are Saying About Healthcare Affordability
By Lawrence Wilson “Yes, I do have opinions about this,” said Milwaukee resident Addaru Valentine just after voting in Wisconsin’s...
UAE Accuses Iran of Attacking Abu Dhabi National Oil Company Vessel in Strait of Hormuz
By Jacki Thrapp The United Arab Emirates (UAE) accused the Iranian regime of attacking an Abu Dhabi National Oil Company...
Federal Judge Declines to Block Border Wall Construction on Arizona Tribal Land
By Aldgra Fredly A federal judge on Aug. 14 refused to block the Trump administration from building a border wall...
Wall Street Review: S&P 500 Hits Record High as Inflation Cools, Earnings Stay Strong
By Panos Mourdoukoutas The S&P 500 climbed to a fresh record high this week, powered by new data showing inflation...
Fauci Refuses to Appear Before 2nd Senate Panel After Contempt Vote
By Tom Ozimek Dr. Anthony Fauci has declined a request to appear voluntarily before a second Senate panel, days after...
HHS Report on Alleged Pediatric Gender-Treatment Fraud: 5 Key Takeaways
By Stacy Robinson A report released Aug. 13 by the Department of Health and Human Services (HHS) has shined a...